Clinical experience of methotrexate in Crohn's disease: Response, safety and monitoring of treatment

Postgraduate Medical Journal

Volumn 86, Issue 1014, 2010, Pages 208-211

  Parker, Richard ^a   Dixit, Anyinda ^a   Fraser, Aileen ^a   Creed, Tom J ^a   Probert, Chris S ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; METHOTREXATE; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; MALE; MEDICAL RECORD REVIEW; NAUSEA AND VOMITING; PANCYTOPENIA; PARESTHESIA; PATIENT COMPLIANCE; PATIENT MONITORING; RETROSPECTIVE STUDY; TEACHING HOSPITAL; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE; UNITED KINGDOM; ADOLESCENT; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950823180     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2009.085787     Document Type: Article

References (14)

1. Rang HP, Dale MM, Ritter JM, et al. Pharmacology. 5th edn. Edinburgh: Churchill Livingstone, 2003.
2. Egan LJ, Sandbourne WJ. Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc 1996;71:69-80.
3. Carter MJ, Lobo AJ, Travis SPL, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl V):v1-16. (Pubitemid 39120096)
4. Feagan BG, Rochon J.Fedorak RN. Methotrexate for the management of Crohn's disease. the North American Crohn's study group investigators. N Engl J Med 1995 332:292-7.
5. Feagan BG, Fedorak RN, Irvine EJ, et al. A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-32. (Pubitemid 30341531)
6. Soon SY, Ansari A, Yaneza M, et al. Experience with the use of low-dose methotrexate for inflammatory bowel disease. Eur J Gastroenterol Hepatol 2004;16:921-6. (Pubitemid 39179664)
7. Fraser AG, Morton D, McGovern D, et al. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:693-7. (Pubitemid 34407516)
8. Hayee BH, Harris AW. Methotrexate for Crohn's disease: experience in a district general hospital. Eur J Gastroenterol Hepatol 2005;17:893-8. (Pubitemid 41192125)
9. Charpignon C, Beau P. Methotrexate as single therapy in Crohn's disease: Is it's long term efficacy limited? Gastroenterol Clin Biol 2008;32:153-7. (Pubitemid 351625545)
10. Cairns AJ, Al-Rifia A, Robinson A, et al. Methotrexate in Crohn's Disease; A Useful Alternative? Gut 2009;58(Suppl 1):A56 Abstract PM146.
11. Filer A, Freeguard J, Rowe I. Letter to the Editor. Rheumatology 2003;42:397-8.
12. Baron SE, Wilson Cl. A Yorkshire regional audit on methotrexate monitoring (Abstract of Poster). Br J Dermatol 2003;149 (Suppl):19. P-1.
13. Martin LA, Blackford S. Regional audit of methotrexate prescribing and monitoring (abstract of Poster). Br J Dermatol 2005;153(Suppl 1):32. P-38.
14. Ludlow H, Hurley J, Dolwani S. The use of email and text messaging to remind patients to have blood monitoring whilst on immunosuppresants. Gut 2009;58 (Suppl 1):A62. Abstract PM160.